Overview
- The new laboratory enables work from early product development through manufacturing and final formulation, moving Biovac beyond fill‑finish activities.
- The Gates Foundation has provided about $15 million in grants to Biovac, including support for oral cholera vaccine technology transfer and mRNA preparation.
- The facility includes mRNA drug‑substance capability, a nanoparticle formulation suite, bacterial and cell culture areas, and secured cell‑bank storage.
- Officials frame the lab as a step toward vaccine self‑reliance in line with the African Union goal for 60% local production by 2040, up from about 1% today.
- South Africa says Biovac will seek financing for a proposed multi‑vaccine plant targeting roughly 500 million doses per year.